NCT05093608

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

An Investigator-initiated Phase I Study of SELINEXOR in Combination With Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Selinexor Pill	Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
DRUG	Bevacizumab	Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
DRUG	Atezolizumab	Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.

Timeline

• Start date: 2021-11-03
• Primary completion: 2022-10-12
• Completion: 2022-10-12
• First posted: 2021-10-26
• Last updated: 2022-10-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study